Pyruvate dehydrogenase complex (PDC) deficiencies are a major class of mitochondrial diseases, limiting oxidation of carbohydrate for energy production, especially important in the brain. No definitive treatment of these disorders has been established. The proposed "Natural History and Advanced Genetic Study of Pyruvate Dehydrogenase Complex Deficiencies" will establish a longitudinal natural history database for PDC deficiencies, integrating our data with the NAMDC registry, creating an additional NAMDC natural history sub-database specific to PDC deficiencies, and include clinically detailed and relevant data elements that are derived from patient/family observations. We will enroll a substantial number of diverse subjects with confirmed PDC deficiencies and determine the genetic basis and pathophysiology of up to a third of PDC patients who currently have not been found to have an identified mutation in any of the "primary" PDC-specific genes.
Our specific aims will be: 1) to establish a PDC-specific NAMDC database within the NAMDC Patient Registry, enroll 150-200 subjects through the NAMDC network, collect detailed diagnostic and clinical information with input from the subjects and their families, monitor blood tests for metabolic and treatment markers, and follow them for 3-4 years;2) to use comprehensive advanced genetic analysis technologies (whole exome sequencing and a panel of 23 selected known genes) to find mutations in those subjects in whom none has been found, in collaboration with the NAM DC-sponsored international data exchange network (MSeqDR);and 3) to correlate these clinical and genetic findings to determine if there are different types of PDC deficiencies that may respond to different treatments, and to identify measurable clinically relevant outcomes and promising forms of treatment that could be evaluated in ongoing and future controlled clinical intervention trials.

Public Health Relevance

This project will establish a NAMDC Patient Registry and genetic databases specific to PDC deficiencies with new clinical information, including patient/family reported outcomes and response to treatments. It will increase knowledge of the;genetic and biochemical causes of PDC deficiencies relevant to diagnosis, prognosis, and potential different modes of treatment. This project will interact with ongoing and future clinical trials and will provide useful information for planning such trials.

National Institute of Health (NIH)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZTR1)
Program Officer
Gwinn, Katrina
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
New York
United States
Zip Code
Peverelli, Lorenzo; Gold, Carl A; Naini, Ali B et al. (2014) Mitochondrial myopathy with dystrophic features due to a novel mutation in the MTTM gene. Muscle Nerve 50:292-5
Balreira, Andrea; Boczonadi, Veronika; Barca, Emanuele et al. (2014) ANO10 mutations cause ataxia and coenzyme Q?? deficiency. J Neurol 261:2192-8
Garcia-Diaz, Beatriz; Garone, Caterina; Barca, Emanuele et al. (2014) Deoxynucleoside stress exacerbates the phenotype of a mouse model of mitochondrial neurogastrointestinal encephalopathy. Brain 137:1337-49
Garone, Caterina; Garcia-Diaz, Beatriz; Emmanuele, Valentina et al. (2014) Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency. EMBO Mol Med 6:1016-27
Pascual, Juan M; Liu, Peiying; Mao, Deng et al. (2014) Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement. JAMA Neurol 71:1255-65
Paradas, Carmen; Camano, Pilar; Otaegui, David et al. (2013) Longitudinal clinical follow-up of a large family with the R357P Twinkle mutation. JAMA Neurol 70:1425-8
Saneto, Russell P; Sedensky, Margret M (2013) Mitochondrial disease in childhood: mtDNA encoded. Neurotherapeutics 10:199-211
DiMauro, Salvatore (2013) Mitochondrial encephalomyopathies--fifty years on: the Robert Wartenberg Lecture. Neurology 81:281-91
Saneto, Russell P; Cohen, Bruce H; Copeland, William C et al. (2013) Alpers-Huttenlocher syndrome. Pediatr Neurol 48:167-78
Melia, Maria J; Kubota, Akatsuki; Ortolano, Saida et al. (2013) Limb-girdle muscular dystrophy 1F is caused by a microdeletion in the transportin 3 gene. Brain 136:1508-17